

Antibodies against GPCR

Carlotta Meyer¹, Harald Heidecke¹

¹CellTrend GmbH, Luckenwalde, Germany

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. GPCR-autoantibodies in transplantation
 - 3.1. Rejection of kidney transplantation
 - 3.2. Heart transplantation
 - 3.3. Hand transplantation
 - 3.4. Liver-transplantation
 - 3.5. Lung transplantation
 - 3.6. Stem Cell Transplantation
4. GPCR-Autoantibodies in cardiovascular disease
 - 4.1. Chronic heart failure
 - 4.2. Preeclampsia
 - 4.3. Malignant and pulmonary hypertension
 - 4.4. Thromboangiitis obliterans (Buerger's disease)
5. GPCR-Autoantibodies in neurological disorders
 - 5.1. Chronic fatigue syndrome (CFS/ME)
 - 5.2. Alzheimer's disease
 - 5.3. Complex regional pain syndrome
 - 5.4. Orthostatic hypotension and postural tachycardia syndrome
 - 5.5. NMDA encephalitis
6. GPCR-autoantibodies in bona-fide autoimmune-diseases
 - 6.1. Systemic sclerosis
 - 6.2. Sjögren's syndrome
7. GPCR-autoantibodies in cancer
8. Conclusions
9. References

1. ABSTRACT

G-protein-coupled receptors (GPCRs) are the largest family of receptors in humans. GPCRs are seven-transmembrane receptors that are activated by the binding of a ligand to the extracellular domain. In addition to the endogenous ligands, auto-antibodies (aab) can also bind to the GPCRs. They can activate different and specific cellular pathways which contribute to various diseases. In this review, the authors summarize the knowledge about antibodies targeting GPCRs and their effects and relevance in the pathogenesis of various diseases and their use in clinical diagnostics. We highlight the role of different activating anti-GPCR aab in solid organ transplantations, stem cell transplantations, systemic sclerosis, preeclampsia, chronic fatigue syndrome, cardiovascular diseases, Alzheimer's disease, and cancer.

2. INTRODUCTION

G protein coupled receptors compose a family of receptors which are located in cell membranes and in endosome membranes. GPCRs are the biggest protein superfamily with more than 1000 members. Of the approximately 21,000 genes in humans, approximately 1000 are GPCR genes (1). The main structural element of a GPCR is the seven trans-membrane receptor domain which is able to use GTP-binding proteins for signal transduction. The research considering the function and clarifying the structure of GPCRs was awarded by the Nobel Prizes for Medicine in 1971 to E. W. Sutherland, in 1974 to A. G. Gilman and M. Rodell, and in 2012 by the Nobel Prize for Chemistry to B. Kobilka and R. Lefkowitz. Pharmaceuticals created to target GPCR structures made up to more than 30% of all prescribed

drugs in 2017 (2). The most well-known drugs are antihistamines, angiotensin receptor inhibitors, beta receptor blockers, dopamine agonists, neuroleptics, opioids, and triptanes.

Pathophysiologic antibodies against GPCRs were initially described in 1956 in Graves disease. In this context, the antibodies are directed against the TSH (thyroidea stimulating hormone) receptor and stimulate the proliferation of the thyroid gland and the absorption of iodine. In Hashimoto's thyroiditis the antibodies against the TSH receptor lead to the destruction the thyroid gland which is associated with a loss of function (3). The main target of autoimmunity in Hashimoto is thyreoglobuline. Moreover, Hashimoto is a mostly t-cell mediated disease whereas Graves is a mainly B-cell mediated disease (4, 5).

In a groundbreaking work Sterin-Borda *et al.* described for the first time anti-beta adrenergic aab associated with Chagas disease (6). Wallukat *et al.* discovered anti-beta-1 adrenergic receptor aab in patients with idiopathic dilated cardiomyopathy (7). These findings were confirmed by Magnusson *et al* in their landmark research work. The authors described anti-beta-1 adrenergic receptor aab in sera samples of dilated cardiomyopathy patients (8). Venter *et al.* identified anti-beta-2 adrenergic receptor aab in sera samples of allergic asthma patients (9, 10).

In the last couple of years, very intensive research work was performed on antibodies against GPCRs mainly by German research groups. V. Homuth *et al.* initially described the AT1R-Ab in 1999 (11). Based on this first description, D. Dragun *et al.* examined the anti-AT1R aab in transplantation medicine (12). Based on Dragun's work, detection of AT1R-Abs is now almost worldwide used in routine diagnosis and has been interpolated into transplantation medicine. Alongside D. Dragun, G. Riemekasten, D. N. Muller, R. Dechend *et al.* have carried out groundbreaking research in the area of antibodies against the angiotensin receptor and endothelin receptor. Antibodies against the beta adrenergic receptor were examined very intensively by F. Boege, R. Jahns, V. Jahns, M. J. Lohse, G. Wallukat, I. Schimke, R. Hetzer, M. Ungerer, and by H. P. Holthoff *et al.* C. Scheibenbogen *et al.* described anti-beta-adrenergic receptor aab and anti-muscarinic cholinergic receptor aab in chronic fatigue syndrome (CFS/ME) for the first time indicating their important role in various diseases. L. Gill *et al.* and M. Bimmler *et al.* described for the first time antibodies against GPCRs in the case of Alzheimer's disease.

In the following review the author will give an overview of antibodies against GPCRs and their current relevance in clinical diagnostics of (i) vascular transplant rejection, (ii) cardiovascular diseases, (iii) neurological disorders, (iv) bona-fide autoimmune diseases, and (v) cancer-associated syndromes.

3. GPCR-AUTOANTIBODIES IN TRANSPLANTATION

3.1. Rejection of kidney transplantation

D. Dragun, D. N. Müller, and R. Dechend *et al* described AT1R-Ab as a risk factor for a rejection after kidney transplantations for the first time in 2005 (12). In a translational approach, they identified the role of anti-AT1R aab as drivers for non-HLA-dependent transplant rejections.

N. L. Reinsmoen *et al.* showed for the first time a correlation between anti-AT1R-aab levels and antibody-mediated rejection (AMR) in patients without antibodies against human leukocyte antigen (HLA) or major histocompatibility class I chain-related gene A (MICA) (13). Sera from 63 recipients were determined to have no HLA- donor-specific HLA antibodies (DSA) and no donor-specific MICA antibodies pre-transplant and at the time of acute rejection AR 16 of these recipients were diagnosed with AR including seven with AMR and nine with cellular AR (cell-mediated rejection). High-binding AT1R antibodies were identified in six of seven in the AMR+ group, but in none of nine patients with the cell-mediated rejection ($P=0.0009$).

Anti-AT1R aab are an independent risk factor for the loss of function of kidneys after a *Transplantation*. P. I. Terasaki *et al.* tested anti-AT1R aab and DSA in pre and post-transplant sera from 351 consecutive kidney recipients (14). 134 patients have biopsy-proven rejection and/or lesions and 217 remain free of rejections (control group patients). The rate with rejection or lesions of anti-AT1R was significantly higher compared to the control group (18% vs. 6%, $p < 0.001$). Moreover, 79% of patients with rejection or lesions with anti-AT1R aab lost their grafts (vs. 0% in the control group). Anti-AT1R aab levels increased post-transplant in 58% of the patients with graft failure. Patients with both anti-AT1R aab and DSA had lower graft survival than those with DSA alone (log-rank $p = 0.007$). Multivariate analysis showed that anti-AT1R aab levels above the cut-off were an independent predictor of graft failure in the abnormal biopsy group (ABG), alone (HR: 6.6.) and in the entire population (HR: 5.4.).

In addition, J.P. Souillou *et al.* showed that the presence of pre-transplant anti-AT1R aab are an independent risk factor for long-term graft loss in association with a higher risk of early acute rejection (AR) episodes (15). The study included 599 kidney recipients between 1998 and 2007 from Nantes, France. Patients with anti-AT1R aab levels >10 U had a 2.6.-fold higher risk of graft failure from 3 years post-transplantation onwards ($p = 0.0005$) and a 1.9.-fold higher risk of experiencing an AR episode within the first 4 months of transplantation ($p = 0.0393$).

In the following years a higher risk of a rejection after kidney transplantation related to the presence of anti-AT1R aab was confirmed by more groups (16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30). Furthermore anti-AT1R aab are a marker for the deterioration of organ function after transplantation independent of or together with donor-specific antibodies (31, 32, 33, 34, 35, 36, 37). Moreover, recurrence of focal segmental glomerulosclerosis (FSGS) in the kidneys post transplantation is a major problem. The detection of anti-AT1R aab levels before transplantation appears to be a helpful biomarker in identifying patients at high risk of post-transplant FSGS recurrence (34, 38, 39).

Due to the overwhelming evidence NL Reinsmoen, Cedar Sinai Los Angeles, stated in a review (40) the absolute necessity to stratify the immunological risk of patients before kidney transplantation (and probably heart transplantation) by examining HLA as well as non-HLA antibodies. Hence, she voted for the implementation of tests determining anti-AT1R aab in the profile of routine clinical antibody analyses Profile (41). In addition, the XIII Banff meeting, associated with the Canadian Society of Transplantation in Vancouver, reviewed the clinical impact of the relationship of donor-specific antibody tests (anti-HLA and non-HLA) with transplant histopathology for the first time (42). It was highlighted that anti-AT1R aab can produce allograft injury alone or together with anti-HLA DSAs. Because rising healthcare costs dictate judicious use of laboratory testing, the department of Medicine, Johns Hopkins University School of Medicine, Baltimore sought to define characteristics of kidney transplant recipients who may benefit from screening for anti-AT1R aab (39). Philogene MC, Montgomery RA, Leffell MS, Zachary AA *et al.* investigated Kidney recipients transplanted between 2011 and 2016 at Johns Hopkins, for anti-AT1R aab. Pre-transplant antibody levels were compared to clinical and biopsy indications of graft dysfunction. Biopsies were graded using the Banff 2009-2013 criteria. Patients with focal segmental glomerulosclerosis (FSGS) showed higher titers of anti-AT1R aab at time of transplantation ($p=0.04$). In addition, recipients who were positive for anti-AT1R aab prior to transplantation had increases in serum creatinine within 3 months post-transplantation ($p<0.0001$) and developed abnormal biopsies earlier than did anti-AT1R aab negative patients (126 days versus 368 days respectively; $p=0.02$).

3.2. Heart transplantation

Anti-AT1R aab are strongly associated with antibodies against the endothelin receptor type-A (ETAR) and the ab levels correlate with each other (43). In heart transplant recipients, cardiac allograft vasculopathy (CAV) is a major factor of morbidity and mortality in the long-term graft outcome. R. Hetzer *et al.* discovered an association between

elevated levels of anti-AT1R and anti-ETAR aab with early onset of microvasculopathy as well as with antibody mediated rejection (AMR) and with cellular-mediated rejection (CMR) (44). In a study of 30 cardiac transplant recipients, patients with high pre-transplant levels of anti-AT1R and anti-ETAR aab presented CMR, AMR, and microvasculopathy more often than patients without these antibodies at one year post-transplant ($p=0.041$, $p=0.0002$, and $p=0.048$, respectively).

J. Kobashigawa established that the presence of both DSA and non-HLA specific antibodies appeared to increase the risk of heart allograft rejection (45). In 200 heart recipients, freedom from AMR and/or CMR was significantly decreased at two years' post-transplant when both de novo DSA and increased AT1R antibodies levels were identified; the hazard ratio was 7.1 for patients with de novo DSA ($P<0.0002$), 2.0 for patients with anti-AT1R aab levels >12 U ($P=0.2$), and 10.5 when both de novo DSA and AT1R antibody levels >12 were considered ($P<0.0001$).

These two studies (44, 45) in heart transplantation indicate that antibodies to the non-HLA antigens AT1R and ETAR have a negative impact on heart allograft outcome. Therefore anti-AT1R and anti-ETAR aab were described in the Banff 2015 Heart Meeting Report (46). In detail, P. Bruneval *et al.* indicate that newly ELISAs allow a reliable detection of anti-AT1R and anti-ETAR aab (CellTrend GmbH, Luckenwalde, Germany). These reagents together with the availability of proficiency testing programs have allowed their implementation in testing for clinical *Transplantation*.

A few weeks ago N. Reinsmoen *et al.* published the development of anti-AT1R aab after mechanical circulatory support device implantation (47). The implantation of mechanical circulatory support devices significantly increases anti-AT1R aab levels. The saturated level of anti-AT1R-aab is associated with lower patient survival post implantation.

3.3. Hand transplantation

Banasik *et al.* investigated the presence of anti-AT1R and anti-ETAR aab in five patients with hand transplantations (48). Both anti-AT1R and anti-ETAR aab were found strongly positive in one patient who repeatedly developed acute rejection episodes. Therefore, further investigations are necessary to confirm a possible association between the rejection and high levels of anti-AT1R and anti-ETAR aab.

3.4. Liver-transplantation

O'Leary *et al.* identified the role of anti-AT1R and anti-ETAR aab and the interaction between HLA

DSA and non-HLA autoantibodies also in liver transplant patients (49). They analyzed 1269 recipients of primary liver transplantation from January of 2000 to April of 2009 with known HLA DSA status for anti-AT1R and anti-ETAR aab pre and one year post liver *Transplantation*. The combination of anti-AT1R or anti-ETAR aab and HLA DSA was associated with an increased mortality risk. Isolated de novo anti-AT1R and anti-ETAR aab were associated with an increased risk of rejection and progression of fibrosis. Ohe *et al.* investigated 81 pediatric patients who stopped immunosuppression (IS) after living-donor liver transplants at Kyoto University Hospital in a cross-sectional study (50). After withdrawal of immunosuppression high incidence of long-term progressive graft fibrosis is a major challenge for these patients. In this study, the authors showed that all patients with a high-level of both HLA DSA and anti-AT1R aab were found to have advanced fibrosis ($p < 0.001$).

3.5. Lung transplantation

Reinsmoen *et al.* determined the impact of anti-AT1R and of anti-ETAR aab on graft outcomes in lung transplantation (51). Pre-transplant and post-transplant sera from 162 lung recipients transplanted between 2011 and 2013 at Cedars-Sinai Medical Center, Los Angeles, Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, and University of Texas Health Science Center, San Antonio, were tested for the anti-AT1R and anti-ETAR aab levels using the enzyme-linked immunosorbent assay (CellTrend GmbH). There was a negative impact on antibody mediated rejection (AMR)-free survival for those recipients with increased pre-transplant levels of anti-AT1R ($p = 0.014$) and anti-ETAR aab ($p = 0.005$). These findings suggest the importance to stratify the patient's immunologic risk by assessing both the HLA and non-HLA-specific antibodies.

3.6. Stem cell transplantation

Riemekasten *et al.* reported the association between anti-AT1R and anti-ETAR aab and an autoimmune disorder with clinical fibrotic symptoms developed by patients with systemic sclerosis (43). The chronic graft-versus-host disease (cGVHD) after hematopoietic stem cell transplantation may have similar clinical fibrotic features and its pathogenesis could be similar to systemic sclerosis. In addition, Riemekasten *et al.* described the presence of anti-CXCR3 and anti-CXCR4 aab in systemic sclerosis associated with fibrosis (52, 110).

Based on these findings, Chiron *et al.* investigated the association of anti-AT1R aab and cGVHD in patients after stem cell transplantation (53). Sera from 87 patients including 45 hematopoietic stem cell transplantation patients with extensive cGVHD and 42 without cGVHD were retrospectively analyzed

for the presence of anti-AT1R aab using an enzymatic immunoassay (CellTrend GmbH). In the cGVHD group, anti-AT1R aab levels were significantly higher compared to the non-cGVHD group ($p = 0.04$, 24.4% vs 7.1%).

By analyzing sera from 205 patients, Taniguchi *et al.* showed that patients with increasing levels of anti-AT1R aab during engraftment had significantly higher chance of developing acute GVHD ($p = 0.03$) as those lacking this complication (54).

Luft *et al.* identified antibodies against CXCR3 in acute GVHD (55). The authors measured the anti-CXCR3 aab levels in 98 patients with high grade (grade 3 and 4) acute intestinal GVHD (CellTrend GmbH). The group showed significantly decreased anti-CXCR3 aab concentrations compared to the levels obtained before conditioning ($p < 0.001$). In multivariable analyses decreased concentrations of anti-CXCR3 aab at disease onset were strong predictors of survival after acute GVHD. High anti-CXCR3 aab levels were protective in patients with low endothelial activation and stress index (EASIX), an endothelial risk score.

4. GPCR-AUTOANTIBODIES IN CARDIOVASCULAR DISEASE

4.1. Chronic heart failure

Aab targeting a variety of GPCRs are described in chronic heart failure and are comprehensively summarized by Boivin-Jahns *et al.* in this issue of *Frontiers in Bioscience* (56, 57, 58, 59). Antibodies against adrenergic and muscarinic cholinergic receptors are associated with idiopathic dilated cardiomyopathy, Chagas disease and ischaemic heart disease. Sterin-Borda *et al.* described for the first time antibodies associated with Chagas disease, those targeting beta adrenergic receptors expressed on the heart (6). Wallukat *et al.* discovered antibodies against the beta-1 adrenergic receptor in patients with idiopathic dilated cardiomyopathy (7). The ETICS (Etiology, Titre-Course and Survival) study is investigating the role of beta-1 adrenergic receptors in heart diseases (60). Boege and Jahns are working on a validated, good laboratory practice (GLP)-conform measurement of beta-1 adrenergic receptor antibodies for routine use in clinical laboratories (61, 62, 63, 64). This assay is necessary and should be used as a companion diagnostic, this means as a predictor for the response of a therapy with new developed drugs, neutralizing anti-beta-1 adrenergic antibodies or for immunoabsorption therapy (65, 66, 67, 68). ELISAs using peptide coated microtiter plates are not reliable, the plates should be coated with the whole beta-1 adrenergic receptor. The first results with this new ELISA (CellTrend GmbH) are now available. Lund *et al.* measured beta-1 adrenergic receptor antibodies and antibodies against 24 more new targets in ischemic

(n=155) or non-ischemic (n=36) heart failure patients using a full-receptor sandwich ELISA (69). Anti-beta-1 adrenergic receptor antibodies showed correlations with biomarkers of inflammation and myocardial damage, which further modifies their association with disease severity in heart failure. Dungen *et al.* determined anti-beta-1 adrenergic receptor aab in patients of the Cardiac Insufficiency Bisoprolol Study in Elderly (CIBIS-ELD) trial (n=569) at baseline and 12 week follow up after titration of bisoprolol vs. carvedilol (70). Healthy volunteers (n=198) served as controls. The authors summarized that this novel ELISA (CellTrend GmbH), utilizing the full beta1-adrenoceptor, offers the possibility to measure anti-beta1-adrenoceptor aab in the clinical routine. In addition, higher levels of anti-beta1-adrenoceptor aab were found in patients with a lower ejection fraction and higher heart rates indicating a role of anti-beta-1 adrenergic receptor aab in heart failure. At follow up investigations, anti-beta-1 adrenergic receptor aab were higher in patients treated with bisoprolol. The interactions between anti-beta-1 adrenergic receptor aab and beta receptor blockers should be investigated in larger studies. The findings from the CIBIS study could be a first indication that anti-beta-1 adrenergic receptor aab have an impact on the clinical efficacy of beta blockers.

4.2. Preeclampsia

In 1999, V. Homuth *et al.* discovered anti-AT1R aab in general (11). Preeclampsia (PE), a syndrome affecting 5% of pregnancies, which is characterized by hypertension and proteinuria, is a leading cause of maternal and fetal morbidity and mortality. The authors investigated 25 patients with preeclampsia and compared them to 10 pregnant women with essential hypertension and 10 normotensive pregnant women. Using a bioassay based on neonatal rat cardiomyocytes, it was found in immunoglobulin stimulating the AT1R from all 25 patients suffering from preeclampsia whereas all controls showed no effect.

These findings were confirmed and substantiated by Dechend *et al.* in independent studies (71) and in basic research work (72, 73). In addition, Szpera-Gozdziewicz *et al.* showed increased levels of anti-AT1R aab in 16 patients with preeclampsia compared to 17 healthy pregnant women (74). Kellemes *et al.* showed clinical evidence that anti-AT1R aab are elevated in preeclampsia (75, 76).

Staff *et al.* found that levels of anti-PAR-1 (Thrombin-Receptor, CellTrend GmbH) and anti-PAR-2 (Thrombin-like-Receptor-1, CellTrend GmbH) aab were lower ($p < 0.05$) in preeclamptic pregnancies (n=42) compared to normotensive pregnancies (n=46). They have speculated that these antibodies may play a protective role in the development of preeclampsia (77).

4.3. Malignant and pulmonary hypertension

Wallukat *et al.* described anti-alpha adrenergic receptor aab in essential and in malignant hypertension (78, 79). Pulmonary hypertension (PAH) is associated with different diseases. Guo *et al.* described that anti-ETAR aab occurred more frequently in systemic Lupus Erythematosus (SLE) associated PAH than in controls (80). In addition, anti-ETAR aab are identified in systemic sclerosis and correlate with the occurrence of pulmonary hypertension (43, 107).

4.4. Thromboangiitis obliterans (Buerger's disease)

Buerger's disease (thromboangiitis obliterans) is a rare disease of the arteries and veins in the arms and legs (81). Klein-Weigl *et al.* observed the occurrence of various anti-GPCR aab in Buerger's disease.

5. GPCR-AUTOANTIBODIES IN NEUROLOGICAL DISORDERS

5.1. Chronic Fatigue Syndrome (CFS/ME)

Chronic Fatigue Syndrome has an estimated prevalence of 0.2–0.3% (82); it is a frequent and severe chronic disease. Scheibenbogen *et al.* determined antibodies against alpha and beta adrenergic receptors, muscarinic cholinergic receptors 1-5, dopamine receptors, serotonin receptors, AT1R, and ETAR by ELISA (CellTrend GmbH) in sera from chronic fatigue syndrome patients (n=268) and healthy controls (n=108). Anti-beta-2 adrenergic receptors, anti-muscarinic cholinergic receptors 3 and anti-muscarinic cholinergic receptors 4 aab were significantly elevated in CFS patients compared to controls (83). In addition, pre and post-treatment samples from 25 patients treated during the KTS-2 rituximab trial were analyzed for aab against GPCR (84, 85). In patients receiving rituximab and responded to therapy, anti-beta-2 adrenergic receptor and anti-muscarinic cholinergic receptor 4 aab significantly decreased. In contrast, the aab levels in non-responders did not reduce. This is the first sign that anti-beta-2 adrenergic receptor and the anti-muscarinic cholinergic receptor 4 aab could be used as a companion diagnostic for rituximab treatment in chronic fatigue syndrome.

In addition, Scheibenbogen *et al.* showed that immunoadsorption (IA) was effective to remove anti-beta-2 adrenergic receptors aab in chronic fatigue syndrome patients and improve their outcome (86). In detail, elevated anti-beta-2 adrenergic receptor aab rapidly decreased during IA in 9 of 10 patients. Furthermore 6 months later anti-beta-2 adrenergic receptors aab were significantly lower compared to pretreatment. A rapid improvement of symptoms was reported by 7 patients during the IA. 3 of these patients

had long lasting and ongoing moderate to marked improvement for 6 - 12 months, 2 patients had short improvement only and 2 patients improved for several months following initial worsening.

Kämpf *et al.* described for the first time an association between anti-muscarinic cholinergic receptors 3 and anti-muscarinic cholinergic receptors 4 aab and cancer related fatigue syndrome (87).

5.2. Alzheimer's disease

Gill *et al.* investigated aab against 33 targets (CellTrend GmbH) in sera from patients with mild Alzheimer's disease (n=91) and healthy controls (n=102) (88). Aab against the serotonin receptors 5-HT2AR (p=0.004), 5-HT2CR (p=0.0005) and 5-HT7R (p=0.003), Stablin-1 (p=0.001) and complement receptor C5aR (p=0.004) were increased in patients with Alzheimer's disease. Psychomotor speed was associated with anti-dopamine receptor aab (p<0.001), depression with anti-ETAR aab (p<0.001), and visuospatial function with increased levels of serotonin receptor 5-HT1AR aab (p=0.004). This is the first description that the antibodies against GPCRs are dysregulated also in Alzheimer's disease. Bimmler *et al.* described anti-alpha-1 adrenergic anti-beta-2 adrenergic receptor aab (89, 90).

5.3. Complex regional pain syndrome

Complex regional pain syndrome (CRPS, Morbus Sudeck) is a debilitating disease associated with vasomotor, sudomotor, and sensory disturbances in an affected limb or region of the body (91). The pathophysiological mechanisms of CRPS are not fully understood, and anti-beta-2 adrenergic receptors, anti-alpha-1 adrenergic receptors, and anti-muscarinic cholinergic receptors 2 aab have recently been associated with this condition (92, 93). Due to the suspected auto-immune nature of the disease (in at least a subset of patients), steroids, intravenous immunoglobulin (IVIG), and rituximab have been tried and shown to have variable responses (94, 95, 96). There are a few studies that have reported the efficacy of therapeutic plasma exchange (TPE) on this condition (97, 98). 37 out of 44 (84%) of CRPS patients who underwent TPE (5–7 TPEs over 2–3 weeks) had reported positive response in terms of pain and improvement of other systemic symptoms. The majority required ongoing maintenance TPEs and/or immunosuppressive medications and adjunctive therapies, to maintain symptomatic improvement.

5.4. Orthostatic hypotension and postural tachycardia syndrome

Orthostatic hypotension (OH) is frequently associated with autonomic dysfunction caused by a

variety of primary or secondary autonomic disorders (99). OH of varying severity afflicts up to 2% of the adult population (100). Li *et al.* demonstrated in a mechanistic study the association of aab directed toward the anti-beta-2 adrenergic receptors and anti-muscarinic cholinergic receptors 3 aab in patients with demonstrable orthostasis (101). In addition, Yu *et al.* detect anti-beta-1 adrenergic receptors, anti-beta-2 adrenergic receptors, anti-muscarinic cholinergic receptors 2, and anti-muscarinic cholinergic receptors 3 aab in sera samples from OH patients (102).

Postural tachycardia syndrome (POTS) occurs most commonly in young women of child-bearing age, less frequently in males or at older ages (103). Li *et al.* described elevated levels of anti-alpha-1 adrenergic receptors, anti-beta-1 adrenergic receptors, and anti-beta-2 adrenergic receptors aab (104). These findings have been confirmed by us (own unpublished data).

5.5. NMDA encephalitis

Anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis is a disease of the central nervous system (CNS) with prominent neurologic and psychiatric features (105). The disease is associated autoantibodies to NMDAR, a protein involved in memory function and synaptic plasticity. Affected patients develop symptoms ranging from memory deficits, seizures and psychosis, to potentially lethal catatonia, and autonomic instability. The outcome can be much improved by immunosuppressive therapy. However, the clinical phenotype can be nonspecific and Identification of NMDAR autoantibodies is crucial for diagnosis, timely treatment selection, and monitoring.

6. GPCR-AUTOANTIBODIES IN BONA-FIDE AUTOIMMUNE-DISEASES

6.1. Systemic Sclerosis

Aab targeting GPCRs have been characterized in several rheumatic diseases. In particular, anti-GPCR aab have been deeply investigated in patients with Systemic sclerosis (SSc), which is an autoimmune disease mainly characterized features by the development of autoimmunity, vasculopathy and tissue fibrosis. The renin-angiotensin and endothelin systems have been implicated in vasculopathy and fibrosis. Riemenkaster *et al.* identified the association of anti-AT1R and anti-ETAR aab with clinical symptoms of SSc (43). They investigated serum samples from SSc patients from three independent cohorts (n=478) and compared them with healthy controls (n=372) and control diseases (n=311). Antibodies against

AT1R and ETAR were elevated in patients suffering from SSc. Higher levels of anti-AT1R and anti-ETAR aab were associated with different severe disease manifestations and predicted SSc-related mortality. Anti-AT1R and anti-ETAR aab contribute to disease pathogenesis and therefore they should be used as biomarkers for the risk assessment of disease progression.

Avouac *et al.* showed that in patients with SSc (n=90) anti-ETAR aab are strong predictors for digital ulcers in a five year follow-up (106).

In addition, Becker *et al.* investigated patients with SSc related pulmonary arterial hypertension (PAH, n=81) and connective tissue disease-associated PAH (n=110) compared with other forms of pulmonary hypertension (n=106), (107). The predicted outcomes for PAH, associated with SSc, was worse than for the other forms of PAH. Anti-AT1R and anti-ETAR aab are more frequent in SSc related PAH and in connective tissue disease related PAH compared to other forms of pulmonary hypertension. Anti-AT1R and anti-ETAR aab serve as predictors and prognostic biomarkers in SSc related PAH.

Kill postulates that Angiotensin and endothelin-receptor activation via anti-AT1R and anti-ETARaab mediate pathogenic effects, indicating their contribution to pathogenesis of SSc (108, 109).

Weigold *et al.* investigated the role of anti-CXCR3 and CXCR4 aab in systemic sclerosis (110). Chemokine receptors CXCR3 and CXCR4 are involved in fibrosis, a key feature of systemic sclerosis. Anti-CXCR3 and anti-CXCR4 aab were measured in 327 SSc patients and in 234 sera from healthy donors by ELISA (CellTrend GmbH). Patients with SSc-related interstitial lung disease (SSc-ILD) exhibited higher anti-CXCR3 and CXCR4 aab titers, which negatively correlated with lung function parameters. However, patients with deterioration of lung function showed lower anti-CXCR3/4 ab levels compared to those with stable disease.

6.2. Sjögren's syndrome

Sjögren's syndrome (SjS) is a systemic autoimmune disorder characterized by lymphocytic infiltration in the salivary and lacrimal glands, resulting in severe dry mouth or eyes (111). There is strong evidence of anti-muscarinic cholinergic receptors 3 aab to have pathogenetic relevance in SjS and current belief holds that these aab should be used as a biomarker for SjS (112, 113, 114, 115). To evaluate the diagnostic value of anti-muscarinic cholinergic receptors 3 aab in SjS a meta-analysis was performed (116). Eleven

studies were included. The anti-muscarinic cholinergic receptors 3 aab had high specificity but relatively low sensitivity for the diagnosis of SjS, which may be due to the fact that it occurs only in a subgroup of these patients.

7. GPCR-AUTOANTIBODIES IN CANCER

Catar *et al.* described for the first time a decrease of naturally occurring antibodies against PAR1 (Thrombin receptor) in patients with metastatic cancer after kidney transplantation compared to patients with kidney transplantation without cancer (117).

Furthermore, Kreienbring *et al.* shows in this issue of Frontiers in Bioscience that anti-PAR-1 aab correlated significantly with histological grading ($p=0.007$) and was significantly lower in the patient's group compared to healthy controls ($p<0.001$) (118).

8. CONCLUSIONS

Antibodies against GPCR are present in autoimmune and non-autoimmune diseases. Both elevated as well as decreased anti-GPCR ab are present in diseases (119). There are a growing number of antibodies against different GPCR. Current researches indicate the role of anti-GPCR aab patterns as markers of diseases. The role of anti-GPCR aab in disease pathogenesis is an emerging field in different diseases. In addition, studies determining quantity and quality biological spectrum of aab targeting GPCRs in healthy subjects according to sex, age and geographic areas will bring valuable parameters for future investigations.

A major challenge in the field of anti-GPCR aab is the determination of the aab with reliable assays. There are two methods in general, functional assays (so called bioassays) and IgG-binding assays using a variety of antigenic target molecules (ELISAs or similar methods). Many ELISAs employ peptid homologues of the presumed target epitope as capture antigen. Current belief holds that these may not be useful in many cases (63). ELISAs using the full GPCR protein are reliable and have high-through-put ability. A few of these (e.g. anti-AT1R-Ab and anti-ETAR-Ab, CellTrend GmbH) are registered as *in vitro* diagnostics (IvD). Table 1 gives an overview of, which type of assay has been used in the characterisation of GPCR-aab in the various diseases discussed here.

Anti-GPCR aab are another ligand of the receptor with specific effects on the receptor. They are a target for the development of a new class of drugs as well as for new diagnostic tools for the personalized medicine.

Table 1. Methods used for determining GPCR-autoantibodies in human diseases

Disease	Method	Target	Approval ¹
Kidney Transplantation			
	GPCR-membran-ELISA	AT1R	IvD
	GPCR-membran-ELISA	ETAR	IvD
Heart Transplantation			
	GPCR-membran-ELISA	AT1R	IvD
	GPCR-membran-ELISA	ETAR	IvD
Hand Transplantation			
	GPCR-membran-ELISA	AT1R	IvD
	GPCR-membran-ELISA	ETAR	IvD
Liver Transplantation			
	GPCR-membran-ELISA	AT1R	IvD
	GPCR-membran-ELISA	ETAR	IvD
Lung Transplantation			
	GPCR-membran-ELISA	AT1R	IvD
	GPCR-membran-ELISA	ETAR	IvD
Stem Cell Transplantation			
	Protein-ELISA	CXCR3	RUO
Dilated Cardiomyopathy			
	Bioassay	β 1-adrenergic receptor	RUO
	GPCR-membran-ELISA	β 1-adrenergic receptor	IvD
	FACS	β 1-adrenergic receptor	RUO
Chagas Disease			
	Bioassay	β 1-adrenergic receptor	RUO
	Bioassay	β 2-adrenergic receptor	RUO
Ischaemic Heart Disease			
	FACS	β 1-adrenergic receptor	RUO
	Bioassay	β 1-adrenergic receptor	RUO
	GPCR-membran-ELISA	β 1-adrenergic receptor	IvD
Preeclampsia			
	Bioassay	AT1R	RUO
	GPCR-membran-ELISA	AT1R	IvD
	Peptid-ELISA	AT1R	RUO
	Protein-ELISA	PAR1	RUO
Essential Hypertension			
	Bioassay	α -adrenergic receptor	RUO
Malignant Hypertension			
	Bioassay	α -adrenergic receptor	RUO
Pulmonary Hypertension			
	GPCR-membran-ELISA	ETAR	IvD
	Peptid-ELISA	ETAR	RUO
Chronic Fatigue Syndrome			

Antibodies against GPCR

	GPCR-membran-ELISA	β 2-adrenergic receptor	IvD
	GPCR-membran-ELISA	muscarinic cholinergic receptors-3	IvD
	GPCR-membran-ELISA	muscarinic cholinergic receptors-4	IvD
Cancer Related Fatigue			
	GPCR-membran-ELISA	muscarinic cholinergic receptors-3	IvD
	GPCR-membran-ELISA	muscarinic cholinergic receptors-4	IvD
Alzheimer's Disease			
	GPCR-membran-ELISA	Serotonin Receptor 5-HT1AR	RUO
	GPCR-membran-ELISA	Serotonin Receptor 5-HT2AR	RUO
	GPCR-membran-ELISA	Serotonin Receptor 5-HT2CR	RUO
	GPCR-membran-ELISA	Serotonin Receptor 5-HT7R	RUO
	GPCR-membran-ELISA	Dopamine Receptor	RUO
	GPCR-membran-ELISA	ETAR	IvD
	GPCR-membran-ELISA	Complement Receptor 5a	RUO
	Protein-ELISA	Stabilin-1	RUO
	Bioassay	α 1-adrenergic receptor	RUO
	Bioassay	β 2-adrenergic receptor	RUO
Complex Regional Pain Syndrome			
	Peptid-ELISA	α 1-adrenergic receptor	RUO
	Peptid-ELISA	β 2-adrenergic receptor	RUO
	Peptid-ELISA	muscarinic cholinergic receptors-2	RUO
Orthostatic Hypotension			
	Peptid-ELISA	β 1-adrenergic receptor	RUO
	Peptid-ELISA	β 2-adrenergic receptor	RUO
	Peptid-ELISA	muscarinic cholinergic receptors-2	RUO
	Peptid-ELISA	muscarinic cholinergic receptors-3	RUO
Postural Tachycardia Syndrome			
	Peptid-ELISA	α 1-adrenergic receptor	RUO
	Peptid-ELISA	β 1-adrenergic receptor	RUO
	Peptid-ELISA	β 2-adrenergic receptor	RUO
Systemic Sclerosis			
	GPCR-membran-ELISA	AT1R	IvD
	GPCR-membran-ELISA	ETAR	IvD
	Protein-ELISA	CXCR3	RUO
	Protein-ELISA	CXCR4	RUO
Sjögren's Syndrome			
	Peptid-ELISA	muscarinic cholinergic receptors-3	RUO
	GPCR-membran-ELISA	muscarinic cholinergic receptors-3	IvD
Cancer			
	Protein-ELISA	PAR1	RUO

¹IvD = *In vitro* Diagnostic. RUO = Research use only.

9. REFERENCES

1. H Schooltink. Tausendsassa unter den Rezeptoren. *Pharmazeutische Zeitung* 09 (2014)
2. J Rassow, K Hauser, R Netzker, R Deutzmann. GPCR. *Biochemie*. 4. Auflage. Thieme, Stuttgart 561 (2016)
3. SM McLachlan, Y Nagayama, PN Pichurin, Y Mizutori, CR Chen, A Misharin, HAAliesky, B Rapoport. The Link between Graves' Disease and Hashimoto's Thyroiditis: A Role for Regulatory T Cells. *Endocrinology* 148 (12), 5724–5733 (2007)
DOI: 10.1210/en.2007-1024
PMid:17823263
4. M Ungerer, J Faßbender, HP Holthoff. Antigen-specific therapy of Graves' disease and orbitopathy by induction of tolerance. *Front Biosci Landmark Ed* (2018)
5. SD Lytton, A Schlüter, JP Banga. Functional Diagnostics for Thyroid Stimulating Hormone Receptor Autoantibodies: Bioassays Prevail Over Binding Assays. *Front Biosci Landmark Ed* (2018)
6. L Sterin-Borda, PM Cossio, MF Gimeno, AL Gimeno, C Diez, PP Laguens, PC Meckert, RM Arana. Effect of chagasic sera on the rat isolated atrial preparation: immunological, morphological and functional aspects. *Cardiovascular Res* 10, 613-622 (1976)
DOI: 10.1093/cvr/10.6.613
7. G Wallukat, A Wollenberger. Effects of gamma globulin fraction of patients with allergic asthma and dilated cardiomyopathy on chronotropic beta adrenoreceptor function in cultured neonatal rat heart myocytes. *Biomed Biochim Acta* 46, 634-639 (1987)
8. Y Magnusson, S Marullo, S Hoyer, F Waagstein, B Andersson, A Vahlne, JGGuillet, AD Strosberg, A Hjalmarson, J Hoebeke. Mapping of a functional autoimmune epitope on the beta 1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. *J Clin Invest.* 86(5), 1658-1663 (1990)
9. JC Venter, CM Fraser, LC Harrison. Autoantibodies to beta 2-adrenergic receptors: a possible cause of adrenergic hyporesponsiveness in allergic rhinitis and asthma. *Science* 207(4437), 1361-1363 (1980)
DOI: 10.1126/science.6153472
PMid:6153472
10. CM Fraser, JC Venter, M Kaliner. Autonomic abnormalities and autoantibodies to beta-adrenergic receptors. *N Engl J Med.* 305(20), 1165-1170 (1981)
11. G Wallukat, V Homuth, T Fischer, C Lindschau, B Horstkamp, A Jüpner, E Baur, E Nissen, K Vetter, D Neichel, JW Dudenhausen, H Haller, FC Luft. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. *J Clin Invest.* 103(7), 945-952 (1999)
12. D Dragun, DN Müller, JH Bräsen, L Fritsche, M Nieminen-Kelhä, R Dechend, U Kintscher, B Rudolph, J Hoebeke, D Eckert, I Mazak, R Plehm, C Schönemann, T Unger, K Budde, HH Neumayer, FC Luft, G Wallukat. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. *N Engl J Med.* 352(6), 558-569 (2005)
13. NL Reinsmoen, CH Lai, H Heidecke, M Haas, K Cao, G Ong, M Naim, Q Wang, J Mirocha, J Kahwaji, AA Vo, SC Jordan, D Dragun. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. *Transplantation.* 90(12), 1473-1477 (2010)
14. M Taniguchi, LM Rebellato, J Cai, J Hopfield, KP Briley, CE Haisch, PG Catrou, P Bolin, K Parker, WT Kendrick, SA Kendrick, RC Harland, PI Terasaki. Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies. *Am J Transplant.* 13(10), 2577-2589 (2013)
15. M Giral, Y Foucher, A Dufay, JP Van Huyen, K Renaudin, A Moreau, A Philippe, B Hegner, R Dechend, H Heidecke, S Brouard, A Cesbron, S Castagnet, A Devys, JP Souillou, D Dragun. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. *Am J Transplant.* 13(10), 2567-2576 (2013)
16. AJ Gareau, C Wiebe, D Pochinco, IW Gibson, J Ho, DN Rush, PW Nickerson. Pre-transplant AT1R antibodies correlate with

- early allograft rejection. *Transpl Immunol.* 46, 29-35 (2017)
17. MA Lim, M Palmer, J Trofe-Clark, RD Bloom, A Jackson, MC Philogene, M Kamoun. Histopathologic changes in anti-angiotensin II type 1 receptor antibody-positive kidney transplant recipients with acute rejection and no donor specific HLA antibodies. *Hum Immunol.* 78(4), 350-356 (2017)
18. I Guzzo, F Morolli, FD Camassei, A Piazza, E Poggi, L Dello Strologo. Acute kidney transplant rejection mediated by angiotensin II type 1 receptor antibodies in a pediatric hyperimmune patient. *Pediatr Nephrol.* 32(1), 185-188 (2017)
19. MC Philogene, S Bagnasco, ES Kraus, RA Montgomery, D Dragun, MS Leffell, AA Zachary, AM Jackson. Anti-Angiotensin II Type 1 Receptor and Anti-Endothelial Cell Antibodies: A Cross-Sectional Analysis of Pathological Findings in Allograft Biopsies. *Transplantation.* 101(3), 608-615 (2017)
DOI: 10.1097/TP.0000000000001231
PMid:27222934 PMCID:PMC5319389
20. S Ilesari, Q Lai, E Favi, F Pisani. Bortezomib-Containing Multimodality Treatment for Antibody-Mediated Rejection with Anti-HLA and Anti-AT1R Antibodies after Kidney Transplantation. *Yonsei Med J.* 58(3), 679-681 (2017)
21. J Lee, KH Huh, Y Park, BG Park, J Yang, JC Jeong, J Lee, JB Park, JH Cho, S Lee, H Ro, SY Han, MS Kim, YS Kim, SJ Kim, CD Kim, W Chung, SB Park, C Ahn, KNOW-KT Study Group. The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal Transplantation. *Nephrol Dial Transplant.* 32(7), 1244-1250 (2017)
22. MH Pearl, RK Leuchter, EF Reed, Q Zhang, RB Ettenger, EW Tsai. Accelerated rejection, thrombosis, and graft failure with angiotensin II type 1 receptor antibodies. *Pediatr Nephrol.* 30(8), 1371-1374 (2015)
23. H Lee, Ji Kim, IS Moon, BH Chung, CW Yang, Y Kim, K Han, EJ Oh. Investigation of Serum Angiotensin II Type 1 Receptor Antibodies at the Time of Renal Allograft Rejection. *Ann Lab Med.* 35(3), 314-320 (2015)
24. J Lee, Y Park, BS Kim, JG Lee, HJ Kim, YS Kim, KH Huh. Clinical implications of angiotensin II type 1 receptor antibodies in antibody-mediated rejection without detectable donor-specific HLA antibodies after renal Transplantation. *Transplant Proc.* 47(3), 649-652 (2015)
25. A Jobert, N Rao, S Deayton, GD Bennett, J Brealey, J Nolan, RP Carroll, D Dragun, PT Coates. Angiotensin II type 1 receptor antibody precipitating acute vascular rejection in kidney Transplantation. *Nephrology (Carlton).* 20 Suppl 1, 10-12 (2015)
26. A Fuss, CM Hope, S Deayton, GD Bennett, R Holdsworth, RP Carroll, PT Coates. C4d-negative antibody-mediated rejection with high anti-angiotensin II type I receptor antibodies in absence of donor-specific antibodies. *Nephrology (Carlton).* 20(7), 467-473 (2015)
27. JW In, H Park, EY Rho, S Shin, KU Park, MH Park, EY Song. Anti-angiotensin type 1 receptor antibodies associated with antibody-mediated rejection in patients without preformed HLA-donor-specific antibody. *Transplant Proc.* 46(10), 3371-3374 (2014)
28. B Kranz, R Kelsch, E Kuwertz-Bröking, V Bröcker, HH Wolters, M Konrad. Acute antibody-mediated rejection in paediatric renal transplant recipients. *Pediatr Nephrol.* 26(7), 1149-1156 (2011)
29. R Kelsch, AS Everding, E Kuwertz-Bröking, E Brand, BM Spriewald, W Sibrowski, M Konrad, D Dragun. Accelerated kidney transplant rejection and hypertensive encephalopathy in a pediatric patient associated with antibodies against angiotensin type 1 receptor and HLA class II. *Transplantation.* 92(10), 57-59 (2011)
30. J Malheiro, S Tafulo, L Dias, S Martins, I Fonseca, I Beirão, A Castro-Henriques, A Cabrita. Deleterious Effect of Anti-Angiotensin II Type 1 Receptor Antibodies Detected Pretransplant on Kidney Graft Outcomes is Both Proper and Synergistic with donor-specific anti-HLA antibodies. *Nephrology (Carlton).* (2018)
31. M Banasik, M Boratyńska, K Kościelska-Kasprzak, O Mazanowska, D Bartoszek, M Zabińska, M Mysza, B Nowakowska, A Halań, P Szyber, D Patrzalek, M Klinger. Long-term follow-up of non-HLA and anti-

- HLA antibodies: incidence and importance in renal *Transplantation*. *Transplant Proc.* 45(4), 1462-1465 (2013)
DOI: 10.1016/j.transproceed.2012.11.025
PMid:23726597
32. MH Pearl, Q Zhang, MF Palma Diaz, J Grotts, M Rossetti, D Elashoff, DW Gjertson, P Weng, EF Reed, E Tsai Chambers. Angiotensin II Type 1 receptor antibodies are associated with inflammatory cytokines and poor clinical outcomes in pediatric kidney *Transplantation*. *Kidney Int.* 93(1), 260-269 (2018)
33. E Cuevas, JM Arreola-Guerra, EA Hernández-Méndez, I Salcedo, N Castelan, NO Uribe-Uribe, M Vilatobá, AG Contreras-Saldívar, AI Sánchez-Cedillo, JB Ramírez, D de Rungs, J Granados, LE Morales-Buenrostro, J Alberú. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies. *Nephrol Dial Transplant.* 31(10), 1738-1745 (2016)
34. MA Mujtaba, AA Sharfuddin, BL Book, WC Goggins, AA Khalil, DP Mishler, JA Fridell, MS Yaqub, TE Taber. Pre-transplant angiotensin receptor II type 1 antibodies and risk of post-transplant focal segmental glomerulosclerosis recurrence. *Clin Transplant.* 29(7), 606-611 (2015)
35. M Banasik, M Boratyńska, K Kościelska-Kasprzak, D Kamińska, S Zmonarski, O Mazanowska, M Krajewska, D Bartoszek, M Zabińska, M Myszk, M Kamińska, A Hałoń, T Dawiskiba, P Szyber, A Sas, M Klinger. Non-HLA antibodies: angiotensin II type 1 receptor (anti-AT1R) and endothelin-1 type A receptor (anti-ETAR) are associated with renal allograft injury and graft loss. *Transplant Proc.* 46(8), 2618-2621 (2014)
DOI: 10.1016/j.transproceed.2014.09.029
PMid:25380879
36. M Banasik, M Boratyńska, K Kościelska-Kasprzak, D Kamińska, D Bartoszek, M Zabińska, M Myszk, S Zmonarski, M Protasiewicz, B Nowakowska, A Hałoń, P Chudoba, M Klinger. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes. *Transpl Int.* 27(10), 1029-1038 (2014)
37. A Fichtner, C Süsal, C Schröder, B Höcker, S Rieger, R Waldherr, JH Westhoff, A Sander, D Dragun, B Tönshoff. Association of angiotensin II type 1 receptor antibodies with graft histology, function and survival in paediatric renal transplant recipients. *Nephrol Dial Transplant.* (2018)
38. S Anwar, DS Larson, N Naimi, M Ashraf, N Culiberk, H Liapis, C Wei, J Reiser, DC Brennan. A case report of adrenocorticotrophic hormone to treat recurrent focal segmental glomerular sclerosis post-transplantation and biomarker monitoring. *Front Med (Lausanne)* 2, 13 (2015)
39. MC Philogene, S Zhou, BE Lonze, S Bagnasco, S Alasfar, RA Montgomery, E Kraus, AM Jackson, MS Leffell, AA Zachary. Pre-transplant Screening for Non-HLA Antibodies: Who Should Be Tested? *Hum Immunol.* (2018)
40. X Zhang, NL Reinsmoen. Impact of Non-Human Leukocyte Antigen-Specific Antibodies in Kidney and Heart *Transplantation*. *Front Immunol.* 8, 434 (2017)
41. NL Reinsmoen. Immunological Risk Stratification by Assessing Both the HLA and Non-HLA-Specific Antibodies: Time to Include Testing for Non-HLA Antibodies in the Routine Clinical Antibody Analysis Profile? *Transplantation* 101(1), 23-25 (2017)
42. A Loupy, M Haas, K Solez, L Racusen, D Glotz, D Seron, BJ Nankivell, RB Colvin, M Afrouzian, E Akalin, N Alachkar, S Bagnasco, JU Becker, L Cornell, C Drachenberg, D Dragun, H de Kort, IW Gibson, ES Kraus, C Lefaucheur, C Legendre, H Liapis, T Muthukumar, V Nickleit, B Orandi, W Park, M Rabant, P Randhawa, EF Reed, C Roufosse, SV Seshan, B Sis, HK Singh, C Schinstock, A Tambur, A Zeevi, M Mengel. The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology. *Am J Transplant.* 17(1), 28-41 (2017)
DOI: 10.1111/ajt.14107
PMid:27862883 PMCID:PMC5363228
43. G Riemekasten, A Philippe, M Näther, T Slowinski, DN Müller, H Heidecke, M Matucci-Cerinic, L Czirják, I Lukitsch, MO Becker, A Kill, JM van Laar, R Catar, FC Luft, GR Burmester, B Hegner, D Dragun. Involvement of functional autoantibodies against vascular

- receptors in systemic sclerosis. *Ann Rheum Dis.* 70(3), 530-536 (2011)
44. NE Hiemann, R Meyer, E Wellnhofer, C Schoenemann, H Heidecke, N Lachmann, R Hetzer, D Dragun. Non-HLA antibodies targeting vascular receptors enhance alloimmuneresponseandmicrovasculopathy after heart Transplantation. *Transplantation* 94(9), 919-924 (2012)
45. NL Reinsmoen, CH Lai, J Mirocha, K Cao, G Ong, M Naim, Q Wang, M Haas, M Rafiei, L Czer, J Patel, J Kobashigawa. Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome. *Transplantation* 97(5), 595-601 (2014)
46. P Bruneval, A Angelini, D Miller, L Potena, A Loupy, A Zeevi, EF Reed, D Dragun, NL Reinsmoen, RN Smith, L West, S Tebutt, T Thum, M Haas, M Mengel, P Revelo, M Fedrigo, JP Duong Van Huyen, GJ Berry. The XIIIth Banff Conference on Allograft Pathology: The Banff 2015 Heart Meeting Report: Improving Antibody-Mediated Rejection Diagnostics: Strengths, Unmet Needs, and Future Directions. *Am J Transplantation* 17, 42–53 (2017)
DOI: 10.1111/ajt.14112
PMid:27862968 PMCID:PMC5363364
47. X Zhang, J Mirocha, T Aintablian, S Dimbil, J Moriguchi, F Arabia, JA Kobashigawa, NL Reinsmoen. Revealing a new mode of sensitization induced by mechanical circulatory support devices: Impact of anti-AT1R antibodies. *Clin Transplant.* (2018)
48. M Banasik, J Jabłęcki, M Boratyńska, D Kamińska, K Kościelska-Kasprzak, D Bartoszek, A Chelmoński, A Hałoń, W Baran, M Klinger. Humoral immunity in hand transplantation: anti-HLA and non-HLA response. *Hum Immunol.* 75(8), 859-862 (2014)
DOI: 10.1016/j.humimm.2014.06.010
PMid:24952209
49. JG O’Leary, AJ Demetris, A Philippe, R Freema, J Cai, H Heidecke, C Smith, B Hart, LW Jennings, R Catar, M Everly, GB Klintmalm, D Dragun. Non-HLA Antibodies Impact on C4d Staining, Stellate Cell Activation and Fibrosis in Liver Allografts. *Transplantation* 101(10), 2399-2409 (2017)
50. H Ohe, Y Uchida, A Yoshizawa, H Hirao, M Taniguchi, E Maruya, K Yurugi, R Hishida, T Maekawa, S Uemoto, PI Terasaki. Association of anti-human leukocyte antigen and anti-angiotensin II type 1 receptor antibodies with liver allograft fibrosis after immunosuppression withdrawal. *Transplantation* 98(10), 1105-1111 (2014)
51. NL Reinsmoen, J Mirocha, CR Ensor, M Marrari, G Chaux, DJ Levine, X Zhang, A Zeevi. A 3-Center Study Reveals New Insights Into the Impact of Non-HLA Antibodies on Lung Transplantation Outcome. *Transplantation* 101(6), 1215-1221 (2017)
52. M Rana, S Pitann, S Sommerlatte, G Marschner, H Heidecke, J Humrich, P Lamprecht, A Müller, O Cabral-Marques, G Riemekasten. Loss of balance in circulating autoantibodies targeting CXCR3/CXCR4 and abnormal receptor expression on peripheral blood leukocytes in systemic lupus erythematosus. DGRH Abstract 16235 (2016)
53. A Chiron, JD Bouaziz, M Carmagnat, R Peffault de Latour R, A Lafaurie-Bergeron, M Robin, A Xhaard, A Toubert, D Charron, N Guigue, G Socié, D Bengoufa. Anti-Angiotensin type 1 receptor antibodies in chronic graft-versus-host disease. *Transplantation* 98(4), 470-474 (2014)
54. M Taniguchi, K Gendzekhadze, JH Lee, D Senitzer. Anti-angiotensin II Type-1 receptor antibodies in failed chimerism after hematopoietic stem cell *Transplantation.* ASHI (2017)
55. T Luft, H Heidecke, A Radujkovic, AD Ho, P Dreger. CXCR3 autoantibodies and ligands in acute GVHD – bridging endothelial and T cell pathology. *EBMT* (2017)
56. LR Herda, SB Felix, F Boege. Drug-like actions of autoantibodies against receptors of the autonomous nervous system and their impact on human heart function. *Br J Pharmacol.* 166(3), 847-857 (2012)
57. U Nussinovitch, Y Shoenfeld. The clinical significance of anti-beta-1 adrenergic receptor autoantibodies in cardiac disease. *Clin Rev Allergy Immunol.* 44(1), 75-83 (2013)
58. R Jahns, V Boivin, MJ Lohse. Beta(1)-Adrenergic receptor function, autoimmunity, and pathogenesis of dilated cardiomyopathy. *Trends Cardiovasc Med.* 16(1), 20-24 (2006)

59. V Boivin-Jahns, R Jahns. GPCR-autoantibodies in chronic heart failure. *Front Biosci Landmark Ed* (2018)
60. G Ertl, R Jahns, CE Angermann, S Störk, N Deubner, D Berliner, MJ Lohse, V Jahns, A Schlipp, M Löffler, O Brosteanu, G Gelbrich, C Prettin, B Saume, R Kandolf, M Klingel, W Bauer, G Herrmann, Stürmer J, Pauschinger M, Lerch R, Schunkert H, Hünig T, Kerkau T, Beyersdorf N, Kocoski V, Caforio AL, SB Felix, M Fu, TJ Dengler, R Dietz, F Mehrhof, C Ozcelik, M Posch, HP Schultheiss, U Kühl, R Dechend, DN Müller, R Erbel, G Hasenfuss, B Pieske, R Wachter, F Edelmann, A Staudt, H Katus, Z Kaya, B Maisch, S Pankuweit, AA Caforio, S Iliceto, U Sechtem, T Schäufele, H Fsadni, C Nienaber, M Rauchhaus, S Frantz, O Ritter, C Wanner, F Breunig, V Krane, VO Nikolaev, A Zürn, T Hünig, T Kerkau, B Niklas, V Kocoski. Cardiac beta1-adrenoceptor autoantibodies in human heart disease: rationale and design of the Etiology, Titre-Course, and Survival (ETICS) Study. *Eur J Heart Fail.* 12(7), 753-762 (2010)
61. B Bornholz, B Hanzen, Y Reinke, SB Felix, R Jahns, I Schimke, G Wallukat, F Boege. Detection of DCM-associated β 1-adrenergic receptor autoantibodies requires functional readouts or native human β 1-receptors as targets. *Int J Cardiol.* 202, 728-730 (2016)
62. B Bornholz, T Benninghaus, Y Reinke, SB Felix, D Roggenbuck, V Jahns-Boivin, R Jahns, F Boege. A standardised FACS assay based on native, receptor transfected cells for the clinical diagnosis and monitoring of β 1-adrenergic receptor autoantibodies in human heart disease. *Clin Chem Lab Med.* 54(4), 683-691 (2016)
63. R Jahns, F Boege. Questionable Validity of Peptide-Based ELISA Strategies in the Diagnostics of Cardiopathogenic Autoantibodies That Activate G-Protein-Coupled Receptors. *Cardiology* 131(3), 149-150 (2015)
64. V Boivin-Jahns, R Jahns, F Boege. β 1-Adrenergic receptor autoantibodies in chronic heart failure: Which functional effects are disease relevant and can be addressed diagnostically? *Front Biosci Landmark Ed* (2018)
65. G Münch, V Boivin-Jahns, HP Holthoff, K Adler, M Lappo, S Truöl, H Degen, N Steiger, MJ Lohse, R Jahns, M Ungerer. Administration of the cyclic peptide COR-1 in humans (phase I study): ex vivo measurements of anti- β 1-adrenergic receptor antibody neutralization and of immune parameters. *Eur J Heart Fail.* 14(11), 1230-1239 (2012)
DOI: 10.1093/eurjhf/hfs118
PMid:22968742
66. G Wallukat, J Müller, A Haberland, S Berg, A Schulz, EJ Freyse, R Vetter, E Salzsieder, R Kreutz, I Schimke. Aptamer BC007 for neutralization of pathogenic autoantibodies directed against G-protein coupled receptors: A vision of future treatment of patients with cardiomyopathies and positivity for those autoantibodies. *Atherosclerosis* 244, 44-47 (2016)
DOI: 10.1016/j.atherosclerosis.2015.11.001
PMid:26584137
67. M Dandel, G Wallukat, A Englert, R Hetzer. Immunoabsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension. *Atherosclerosis Supplements* 14, 203-211 (2013)
DOI: 10.1016/j.atherosclerosis.2012.10.029
PMid:23357166
68. M Camino, MD Morales. β -1 Adrenergic receptor autoantibodies in dilated cardiomyopathy in children and response to immunoabsorption therapy. *Front Biosci Landmark Ed* (2018)
69. A Lund, LM Giil, G Slettom, O Nygaard, H Heidecke, JE Nordrehaug. Antibodies to receptors are associated with biomarkers of inflammation and myocardial damage in heart failure. *Int J Cardiol.* 250, 253-259 (2018)
70. TD Trippel, DN Mueller, D Obradovic, F Edelmann, E Tahirovic, N Wilck, G Riemekasten, D Dragun, A Busjahn, H Heidecke, B Pieske, HD Dungen, R Dechend. ELISA based detection of Anti- β 1-Adrenoreceptor Auto-Antibodies in elderly heart failure patients: insights from the CIBIS-ELD trial. *Front Biosci Landmark Ed* (2018)
71. F Herse, S Verlohren, K Wenzel, J Pape, DN Muller, S Modrow, G Wallukat, FC Luft, CW Redman, R Dechend. Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble

- fms-like tyrosine kinase 1 in a gestational age-matched case study. *Hypertension* 53(2), 393-398 (2009)
72. R Dechend, C Viedt, DN Müller, B Ugele, RP Brandes, G Wallukat, JK Park, J Janke, P Barta, J Theuer, A Fiebeler, V Homuth, R Dietz, H Haller, J Kreuzer, FC Luft. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. *Circulation* 107(12), 1632-1639 (2003)
73. MW Cunningham Jr, JM Williams, L Amaral, N Usry, G Wallukat, R Dechend, B LaMarca. Agonistic Autoantibodies to the Angiotensin II Type 1 Receptor Enhance Angiotensin II-Induced Renal Vascular Sensitivity and Reduce Renal Function During Pregnancy. *Hypertension* 68(5), 1308-1313 (2016)
74. A Szpera-Gozdziewicz, T Gozdziewicz, P Wirstlein, E Wender-Ozegowska, GH Breborowicz. The agonistic autoantibodies to the angiotensin II type 1 receptor in pregnancies complicated by hypertensive disorders. *J Matern Fetal Neonatal Med.* 13, 1-5 (2017)
75. AH Siddiqui, RA Irani, SC Blackwell, SM Ramin, RE Kellems, Y Xia. Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity. *Hypertension.* 55(2); 386-393 (2010)
76. C Liu, R Luo, SE Elliott, W Wang, NF Parchim, T Iriyama, PS Daugherty, SC Blackwell, BM Sibai, RE Kellems, Y Xia. Elevated Transglutaminase Activity Triggers Angiotensin Receptor Activating Autoantibody Production and Pathophysiology of Preeclampsia. *J Am Heart Assoc.* 4(12), (2015)
77. K Moe, H Heidecke, R Dechend, AC Staff. Dysregulated levels of novel circulating autoantibodies in preeclampsia. *EuroISShp* 2015 Abstract
78. ML Fu, H Herlitz, G Wallukat, E Hilme, T Hedner, J Hoebeke, AHjalmarson. Functional autoimmune epitope on alpha 1-adrenergic receptors in patients with malignant hypertension. *Lancet* 344(8938), 1660-1663 (1994)
79. HP Luther, V Homuth, G Wallukat. Alpha 1-adrenergic receptor antibodies in patients with primary hypertension. *Hypertension* 29(2), 678-682 (1997)
80. L Guo, M Li, Y Chen, Q Wang, Z Tian, S Pan, X Zeng, S Ye. Anti-Endothelin Receptor Type A Autoantibodies in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension. *Arthritis Rheumatol.* 67(9), 2394-2402 (2015)
81. PF Klein-Weigel, M Bimmle, P Hempel, S Schöpp, S Dreusicke, J Valerius, A Bohlen, JM Boehnlein, D Bestler, S Funk, S Elitok. G-protein coupled receptor autoantibodies in thromboangiitis obliterans (Buerger's disease) and their removal by immunoadsorption. *VASA* 43(5), 347-352 (2014)
82. BM Carruthers, MI van de Sande, KL De Meirleir, NG Klimas, G Broderick, T Mitchell, D Staines, AC Powles, N Speight, R Vallings, L Bateman, B Baumgarten-Austrheim, DS Bell, N Carlo-Stella, J Chia, A Darragh, D Jo, D Lewis, AR Light, S Marshall-Gradisbik, I Mena, JA Mikovits, K Miwa, M Murovska, ML Pall, S Stevens. Myalgic encephalomyelitis: international consensus criteria. *J. Intern. Med.* 270, 327-338 (2011)
83. M Loebel, P Grabowski, H Heidecke, S Bauer, LG Hanitsch, K Wittke, C Meisel, P Reinke, HD Volk, Ø Fluge, O Mella, C Scheibenbogen. Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. *Brain, Behavior, and Immunity* 52, 32-39 (2016)
DOI: 10.1016/j.bbi.2015.09.013
PMid:26399744
84. Ø Fluge, O Bruland, K Risa, A Storstein, EK Kristoffersen, D Sapkota, H Naess, O Dahl, H Nyland, O Mella. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. *PLoS ONE* 6, e26358 (2011)
85. Ø Fluge, K Risa, S Lunde, K Alme, IG Rekeland, D Sapkota, EK Kristoffersen, K Sorland, O Bruland, O Dahl, O Mella. B-Lymphocyte depletion in myalgic encephalopathy/chronic fatigue syndrome. An open-label phase II study with rituximab maintenance treatment. *PLoS ONE* 10, e0129898 (2015)
86. C Scheibenbogen, M Loebel, H Freitag, A Krueger, S Bauer, M Antelmann, W Doehner, N Scherbakov, H Heidecke, P Reinke, HD Volk, P Grabowski. Immunoadsorption to remove β 2 adrenergic receptor antibodies

- in Chronic Fatigue Syndrome CFS/ME. *PLoS ONE* (2018)
87. S Kämpf, C Zelck, M Löbel, P Grabowski, S Banz, I Goppelt, S Bauer, K Wittke, H Heidecke, C Scheibenbogen, F Sotzny. Characterization of M3 and M4 muscarinic acetylcholine receptor epitopes in Chronic Fatigue Syndrome and Cancer-related Fatigue. *Front Biosci Landmark Ed* (2018)
88. LM Giil, CA Vedeler, EK Kristoffersen, JE Nordrehaug, H Heidecke, R Dechend, K Schulze-Forster, DN Muller, VS von Goetze, O Cabral-Marques, G Riemekasten, P Vogelsang, S Nygaard, A Lund, D Aarsland. Antibodies to Signaling Molecules and Receptors in Alzheimer's Disease are Associated with Psychomotor Slowing, Depression, and Poor Visuospatial Function. *J Alzheimers Dis.* 59(3), 929-939 (2017)
89. P Karczewski, P Hempel, R Kunze, M Bimmler. Agonistic autoantibodies to the $\alpha(1)$ -adrenergic receptor and the $\beta(2)$ -adrenergic receptor in Alzheimer's and vascular dementia. *Scand J Immunol.* 75(5), 524-530 (2012)
90. P Karczewski, P Hempel, M Bimmler. Role of alpha1-adrenergic receptor antibodies in Alzheimer's disease. *Front Biosci Landmark Ed* (2018)
91. S Bruehl. Complex regional pain syndrome. *BMJ.* 351, h2730 (2015)
92. D Kohr, P Singh, M Tschernatsch, M Kaps, E Pouokam, M Diener, W Kummer, F Birklein, A Vincent, A Goebel, G Wallukat, F Blaes. Autoimmunity against the beta2 adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome. *Pain* 152, 2690–2700 (2011)
DOI: 10.1016/j.pain.2011.06.012
PMid:21816540
93. E Dubuis, V Thompson, MI Leite, F Blaes, C Maihofner, D Greensmith, A Vincent, N Shenker, A Kuttikat, M Leuwer, A Goebel. Longstanding complex regional pain syndrome is associated with activating autoantibodies against alpha-1a adrenoceptors. *Pain* 155, 2408–2417 (2014)
DOI: 10.1016/j.pain.2014.09.022
PMid:25250722
94. Prednisolone in complex regional pain syndrome. Atalay NS, Ercidogan O, Akkaya N, Sahin F. *Pain Physician* 2014;17: 179–185.
95. A Goebel, M Stock, R Deacon, G Sprotte, A Vincent. Intravenous immunoglobulin response and evidence for pathogenic antibodies in a case of complex regional pain syndrome 1. *Ann Neurol.* 57, 463–464 (2005)
96. JE Hendrickson, ET Hendrickson, EA Gehrie, D Sidhu, G Wallukat, I Schimke, AT Tormey. Complex Regional Pain Syndrome and Dysautonomia in a 14-Year-Old Girl Responsive to Therapeutic Plasma Exchange. *J Clin Apher.* 31(4), 368-374 (2016)
97. E Aradillas, RJ Schwartzman, JR Grothusen, A Goebel, GM Alexander. Plasma exchange therapy in patients with complex regional pain syndrome. *Pain Physician* 18, 383–394 (2015)
98. F Blaes, B Dharmalingam, M Tschernatsch, A Feustel, T Fritz, D Kohr, P Singh, M Kaps, G Szalay. Improvement of complex regional pain syndrome after plasmapheresis. *Eur J Pain* 19, 503–507 (2015)
DOI: 10.1002/ejp.572
PMid:25115658
99. MS Medow, JM Stewart, S Sanyal, A Mumtaz, D Sica, WH Frishman. Pathophysiology, diagnosis, and treatment of orthostatic hypotension and vasovagal syncope. *Cardiol Rev.* 16, 4–20 (2008)
100. PA Low. Prevalence of orthostatic hypotension. *Clin Auton Res.* 18(Suppl 1), 8–13 (2008)
101. H Li, C David, DC Kem, S Reim, M Khan, M Vanderlinde-Wood, C Zillner, D Collier, C Liles, MA Hill, MW Cunningham, CE Aston, X Yu. Agonistic autoantibodies as vasodilators in orthostatic hypotension: a new mechanism. *Hypertension* 59(2), 402–408 (2012)
DOI: 10.1161/HYPERTENSIONAHA.111.184937
PMid:22215709 PMCID:PMC3275920
102. X Yu, S Stavakis, MA Hill, S Huang, S Reim, H Li, M Khan, S Hamlett, MW Cunningham, DC Kem. Autoantibody activation of beta-adrenergic and muscarinic receptors contributes to an “autoimmune” orthostatic hypotension. *J Am Soc Hypertens.* 6, 40–47 (2012)

103. BP Grubb. Postural tachycardia syndrome. *Circulation* 117:2814–2817 (2018)
104. H Li, X Yu, C Liles, M Khan, M Vanderlinde-Wood, A Galloway, C Zillner, A Benbrook, S Reim, D Collier, MA Hill, SR Raj, LE Okamoto, MW Cunningham, CE Aston, DC Kem. Autoimmune Basis for Postural Tachycardia Syndrome. *J Am Heart Assoc.* 3(1), e000755 (2014)
105. E Lazar-Molnar, AE Tebo. Autoimmune NMDA receptor encephalitis. *Clin Chim Acta.* 438, 90-97 (2015)
106. J Avouac, G Riemekasten, C Meune, B Ruiz, A Kahan, Y Allano. Autoantibodies against Endothelin 1 Type A Receptor Are Strong Predictors of Digital Ulcers in Systemic Sclerosis. *J Rheumatol.* 42(10), 1801-1807 (2015)
107. MO Becker, A Kill, M Kutsche, J Guenther, A Rose, C Tabeling, M Witzernath, AA Köhl, H Heidecke, HA Ghofrani, H Tiede, RT Schermuly, N Nickel, MM Hoeper, I Lukitsch, M Gollasch, WM Kuebler, S Bock, GR Burmester, D Dragun, G Riemekasten. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. *Am J Respir Crit Care Med.* 190(7), 808-817 (2014)
108. A Kill, C Tabeling, R Undeutsch, AA Köhl, J Günther, M Radic, MO Becker, H Heidecke, M Worm, M Witzernath, GR Burmester, D Dragun, G Riemekasten. Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. *Arthritis Res Ther.* 16(1), R29 (2014)
109. J Günther, A Kill, MO Becker, H Heidecke, J Rademacher, E Siegert, M Radić, GR Burmester, D Dragun, G Riemekasten. Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients. *Arthritis Res Ther.* 16(2), R65 (2014)
110. F Weigold, J Günther, M Pfeifferberger, OC Marques, E Siegert, D Dragun, A Philippe, AK Regensburger, A Recke, X Yu, F Petersen, R Catar, R Biesen, F Hiepe, GR Burmester, H Heidecke, G Riemekasten. Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis. *Arthritis Research & Therapy* 2018
111. RI Fox. Sjogren's syndrome. *Lancet* 366, 321–331 (2005)
112. L Kovács, I Marczinovits, A György, GK Tóth, L Dorgai, J Pál, J Molnár, G Pokorny. Clinical associations of autoantibodies to human muscarinic acetylcholine receptor 3(213-228) in primary Sjogren's syndrome. *Rheumatology (Oxford)* 44(8), 1021-1025 (2005)
113. J Li, YM Ha, NY Ku, SY Choi, SJ Lee, SB Oh, JS Kim, JH Lee, EB Lee, YW Song, K Park. Inhibitory effects of autoantibodies on the muscarinic receptors in Sjogren's syndrome. *Lab Invest.* 84, 1430–1438 (2004)
114. Y Nakamura, E Wakamatsu, I Matsumoto, M Tomiita, Y Kohno, M Mori, S Yokota, D Goto, S Ito, A Tsutsumi, T Sumida. High prevalence of autoantibodies to muscarinic-3 acetylcholine receptor in patients with juvenile-onset Sjogren syndrome *Ann Rheum Dis.* 67, 136–137 (2008)
115. X Yu, G Riemekasten, F Petersen. Autoantibodies against muscarinic acetylcholine receptor M3 in Sjögren's syndrome and corresponding mouse models. *Front Biosci Landmark Ed* (2018)
116. C Deng, C Hu, S Chen, J Li, X Wen, Z Wu, Y Li, F Zhang, Y Li. Meta-Analysis of Anti-Muscarinic Receptor Type 3 Antibodies for the Diagnosis of Sjögren Syndrome. *PLoS One* 10(1), 0116744 (2015)
117. R Catar, A Philippe, H Heidecke, RP Carroll, D Dragun. Increased mortality and metastatic cancer in renal transplant patients lacking naturally occurring anti-angiogenic antibodies. DTG 2015 Abstract
118. K Kreienbring, A Franz, R Richter, D Dragun, H Heidecke, DN Müller, M Mentze, R Dechend, J Sehoul, EI Braicu. The role of PAR-1 autoantibodies in patients with primary epithelial ovarian cancer. *Anti Cancer Research* (2018)
119. O Cabral-Marques, AH Carvalho-Marques, H Heidecke, G Riemekasten. Loss of balance in normal GPCR-mediated cell trafficking and the development of autoimmune

diseases: a systemic view of receptors, natural ligands and autoantibodies. *Front Biosci Landmark Ed* (2018)

Key Words: GPCR, anti-GPCR antibody, AT1R antibody, non-HLA antibody, beta adrenergic receptor antibody, Review

Send correspondence to: Harald Heidecke, CellTrend GmbH, im Biotechnologiepark, 14943 Luckenwalde, Germany, Tel: 49-3371-6199600, Fax: 49-3371-6199604, E-mail: heidecke@celltrend.de